An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
Price : $35 *
At a glance
- Drugs Adipose-derived-autologous-stem-cell-therapy-U.S.-Stem-Cell (Primary)
- Indications Intervertebral disc degeneration
- Focus Therapeutic Use
- Sponsors U.S. Stem Cell
- 28 Nov 2017 According to a U.S. Stem Cell media release, data will be presented at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS) 2017.
- 15 Mar 2017 Status changed from recruiting to completed.
- 28 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.